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Point mutation or deletion/insertion within the p53 tumour
suppressor gene has been estimated to occur in over half of all
human cancers and may directly contribute to tumour progression
(Chang et al, 1994; Wada et al, 1994; Hainaut et al, 1997). A
number of studies indicate that the canine p53 gene is also mutated
in tumour cells from patients presenting with spontaneous cancers
of different types. These include: thyroid carcinoma (Devilee et al,
1994), oral papilloma (Mayr et al, 1994), osteosarcoma (van
Leeuwen et al, 1997; Johnson et al, 1998), circumanal gland
adenoma (Mayr et al, 1997), lymphoma (Veldhoen et al, 1998) and
mammary tumours (van Leeuwen et al, 1996; Chu et al, 1998;
Mayr et al, 1998). The apparent similarity of p53 inactivation in
tumours of both humans and dogs suggests that investigations into
the molecular aetiology of canine cancer may help to further our
understanding of p53-related neoplasia.
Mammary cancer represents the most common malignant
tumour in female dogs and certain breeds appear to display an
increased cancer predisposition (MacVean et al, 1978; Priester and
McKay, 1980). In order to investigate the role of p53 in mammary
tumour formation and progression, we determined the p53 status
in ten canine cancer patients. Two patients were found to have
tumour-associated p53 mutations, while a third contained germ
line modifications of the p53 gene. These results indicate that both
spontaneous and inherited alterations within the p53 gene are asso-
ciated with canine mammary cancer. In addition, the identification
of germ line p53 gene mutations associated with canine cancer
(this study and Veldhoen et al, 1998) lends support for a critical
role for p53 inactivation in breed predisposition to cancer.
MATERIALS AND METHODS
Plasmids and bacterial strains
The pK9 plasmid contains the wild-type canine p53 cDNA cloned
into pLitmus 29. Canine p53 cDNA fragments isolated from surgi-
cally removed normal and tumour tissue samples of each patient
were cloned into pBluescript SK+. Positively identified mutant
p53 cDNA fragments from patients 5 and 6 were subcloned into
the SacI and MluI sites of pK9 to produce full-length p53 mutant
constructs pMP5 and pMP6 respectively. All plasmids were main-
tained in Escherichia coliXL-1 Blue MRF’.
RNA isolation and p53 cDNA amplification
Total RNA was prepared from a 100mg sample of normal and/or
tumour tissue from each patient using the RNeasy RNA isolation
kit as per the manufacturer’s protocol (Qiagen). Note that normal
tissue was not available for patient 6. Complementary DNA frag-
ments containing p53 coding sequence were amplified from 2m g
total RNA using the Access RT-PCR system as per the manufac-
turer’s protocol (Promega). The primers used in the reaction were
NTup (5¢ GCGGTACCCAATGGAGGAGTCGCAGTCAGAG3¢ )
and CTdn (5¢ GCGGATCCTTAACCTACGTCTGAGTCAAGCC-
CTTCTCTC3¢ ) which amplify the complete open reading frame of
canine p53. The thermocycle programme included a first strand
cDNA polymerization step of 48°C for 45min and 94°C for
2min, then 40 cycles of 94°C (30s), 50°C (1min), 68°C (2min)
and a final polymerization step of 68°C for 7min.
Secondary DNA amplification and p53 cDNA cloning
A second nested DNA amplification reaction was performed to
increase the yield of p53 cDNA product. This reaction used the
primers SacIup (5¢ CAGTCAGAGCTCAATATCGACCCCCCTCT-
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Correspondence to: J MilnerGAGCCAGGAGACATTT3¢) and 9dn (5¢GCGGATCCTGA-
AGGGTGAAATATTC3¢) and amplified a segment of the canine
p53 cDNA containing exons 2 to 9. The 50-ml amplification reaction
included PC2 buffer (50 mM Tris–HCl pH 9.1, 16 mM (NH4)2SO4,
3.5 mM magnesium chloride, 150 mg ml–1 bovine serum albumin
(BSA), 12.5 pmol of each primer, 200 mM dNTPs (dATP, dCTP,
dGTP, dTTP)), 1 ml of first round RT-PCR sample and 1.5 units Taq
Supreme (Helena BioSciences). The thermocycle programme was
identical to that used for the first round reverse transcription poly-
merase chain reaction (RT-PCR) without the initial polymerization
step of 48°C for 45 min.
Canine p53 cDNA fragments isolated from each patient were
digested with the restriction endonucleases SacI and BamHI,
separated on a 1% agarose gel, and isolated by excision and spin
column centrifugation (Pharmacia). Purified p53 cDNA was then
ligated into pBluescript SK+. Positive plasmid clones were
identified by restriction analysis and DNA amplification using
conditions identical to those above and including the primers
5/6up (5¢CGGAATTCCTCCCCTCTCCTCACCAAG3¢) and 8dn
(5¢GCGGATCCTCGCTTGGTACTCCCGGGGG3¢). A minimum
of 14 individual p53 cDNA clones derived from each patient tissue
sample were pooled for sequence analysis. The cloned p53 cDNA
was sequenced using a T7 sequencing kit as per the manufacturer’s
protocol (Pharmacia Biotech).
Amplification of the p53 gene deletion from patient 9
genomic DNA
Genomic DNA was prepared from normal and tumour tissue of
patient 9 using a genomic DNA miniprep kit as per the manu-
facturer’s protocol (Immunogen International). DNA fragments
containing the p53 gene were amplified using the primer pairs
SacIup:9dn, 5/6up:7dn (5¢GCGGATCCTGGAGTCTTCCAGG-
GTGAT3¢), P9.1 (5¢CAGAATTGTGGAACCTGTAAGT3¢):9dn,
and P9.2 (5¢GGCTCCCCACCAGCCCTCTGGG3¢):9dn in a
50-ml reaction containing PC2 buffer, 12.5 pmol of each primer,
50 mM dNTPs, 320 ng genomic DNA, 5 units Taq Supreme
(Helena BioSciences). The thermocycle programme included a
denaturation step of 94°C (7 min), 40 cycles of 94°C (1 min),
62°C (30 s), 68°C (1.5 min), and a final polymerization step
of 68°C for 7 min. The amplified DNA products were electro-
phoresed on a 1% agarose gel. DNA fragments amplified using the
SacIup and 9dn primers were cut with SacI and BamHI and cloned
into the identical sites of pBluescript SK+. Positive clones were
sequenced using a T7 sequencing kit as per the manufacturer’s
protocol (Pharmacia Biotech).
Transcription and translation
Plasmids pMP5 and pMP6 containing mutant p53 cDNA isolated
from patients 5 and 6, respectively, were digested with EcoRI.
Plasmid pK9 containing wild-type canine p53 cDNA was simi-
larly digested with EcoRI. RNA transcription was performed as
described by Veldhoen and Milner (1998). Wild-type and mutant
canine p53 proteins were translated at 30°C in a rabbit reticulocyte
lysate system as described by Gamble and Milner (1988). The effi-
ciency of translation was determined by TCA precipitation on
glass filters followed by scintillation counting.
Immunoprecipitation
Protein conformation was assessed by immunoprecipitation with the
anti-p53 antibodies PAb240, and PAb421 as described by Cook and
Milner (1990). Antibody PAb416, directed towards the large T-
antigen of SV40, was used as a negative control. Immunoprecipitated
proteins were resolved by 15% sodium dodecyl sulphate polyacryl-
amide gel electrophoresis (SDS-PAGE) and visualized by auto-
radiography with Fuji RX film at room temperature.
RESULTS
Identification of tumour-associated p53 gene mutations
Table 1 shows the clinical information for each patient analysed in
this study. The status of the p53 gene in the ten patients was
assessed following routine surgical removal of mammary tumour
material and surrounding normal tissue. Appropriate precautions
were taken to prevent cross-contamination between the two tissue
types during the surgical procedure. (Note: normal tissue was not
available for patient 6.) Total RNA was isolated from both normal
and tumour tissue and p53 cDNA prepared by nested RT-PCR.
The p53 cDNA was subsequently cloned and sequenced. Three of
the dogs (patients 5, 6, and 9) were found to have p53 mutations
while the remaining seven patients exhibited wild-type p53 cDNA
sequence. The p53 mutations observed for patients 5, 6, and 9
were confirmed by a second independent round of cDNA isolation
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Table 1 Clinical information on the canine mammary cancer patients
Patient Age Breed Intact (I)/ Histopathology Prognosis
number (years) Neutered (N)
1 10 Collie cross I Carcinoma Guarded
2 12 Spaniel I Carcinoma Guarded
3 8 Lurcher I Carcinoma Guarded
4 10.5 Border collie I Carcinoma Guarded
5a 10 Labrador I Carcinoma Guarded
Adenoma Guarded
6b –– – – –
7 9 Collie cross N Adenoma Good
8 11 Old English sheepdog I Adenoma Good
9 5 Boxer N Adenoma Good
10 17 Jack Russell terrier I Sarcoma Guarded
aNote: Patient number 5 presented with two discrete mammary tumours. bNo clinical information was available for this patient.and sequencing. All codon positions refer to the canine p53 open
reading frame sequence (Genbank Accession AF060514). Where
necessary, the corresponding human p53 codon positions are also
identified.
Patient 5 presented with two discrete mammary tumours; a
solid carcinoma and an adenoma (Table 1). The adenoma tissue
contained wild-type p53, while a p53 gene mutation was identified
in the solid carcinoma tumour. This point mutation at codon 125
(GCG to GTG) within exon 5 results in a substitution from alanine
to valine (Figure 1) and corresponds to the temperature-sensitive
mutants Ala135Val of murine p53 (Martinez et al, 1991) and
Ala138Val of human p53 (Hirano et al, 1995; Yamato et al, 1995).
Mutation at the equivalent position in the human p53 gene has
been observed in three breast cancer patients (Moll et al, 1992;
Faille et al, 1994). Although not directly investigated, the lack of
detectable wild-type p53 sequence within the carcinoma of patient
5 indicates that allelic loss of the p53 gene may have also occurred
during tumorigenesis (Figure 1).
Patient 6 displayed multiple substitution mutations clustered
within exon 2 of the p53 gene (Figure 2). These point mutations
included substitutions of glutamic acid to aspartic acid at codon 21
(GAA to GAT), a silent mutation of the leucine residue at codon 22
(TTG to CTG), and a substitution of asparagine to lysine at codon
24 (AAC to AAG). A fourth base pair change located within exon
4 of the same p53 allele was also observed at codon 69 (CCC to
CTC) resulting in a substitution of proline for leucine (not shown).
Although relatively rare, multiple p53 gene mutations have been
identified in two human breast cancer patients (Glebov et al, 1994;
Seth et al, 1994). No wild-type p53 cDNA sequence was isolated
from the tumour of patient 6 suggesting a loss of the second p53
allele (Figure 2).
The analysis of patient 9 proved to be very interesting and
revealed mutations within the p53 gene isolated from both normal
tissue and the mammary adenoma tumour. This strongly supports a
germ line origin for these p53 gene alterations. One p53 allele was
found to contain a large deletion of DNA sequence that included
exons three through seven (Figure 3A). The presence of the
internal p53 deletion was confirmed by sequencing both cDNA
and genomic DNA clones derived from normal and tumour tissue.
Mutant-specific amplification of genomic DNA isolated from
normal and tumour tissue of patient 9 also points to a germ line
origin for the p53 deletion mutation (Figure 3B, compare lanes 5
and 6 with lanes 8 and 9). The chromosome breakpoint within this
p53 ‘mini gene’ is shown in Figure 3A and results in a fusion of
introns 2 and 7 of the canine p53 gene. Analysis of the canine p53
gene sequence (Chu et al, 1998) suggests that this deletion may
have originated during DNA replication through a slipped-strand
mispairing mechanism (for example see Huang et al, 1994). This
form of DNA damage would involve two imperfect direct repeat
sequences located within introns 2 (GGACCCCTGC) and 7
(GGCCCCCTGC) of the canine p53 gene and result in loss of the
3¢ repeat sequence and intervening DNA (see Figure 3A).
The second intact p53 allele of patient 9 contained a single base
pair substitution at codon 69 (CCC to CTC) resulting in replacement
of proline with leucine (Figure 4). This Pro69Leu substitution was
observed in both normal and tumour tissue and could potentially
represent a second germ line p53 mutation identified in the same
cancer patient. A similar germ line mutation of the corresponding
position in human p53 (Pro82Leu) has been suggested to influence
the development of human breast cancer (Sun et al, 1996). An alter-
native explanation is that Pro69Leu may represent a polymorphism
in the canine p53 gene. This is suggested by the presence of this
substitution in the tumour of patient 6. Unfortunately, no normal
tissue from patient 6 was available for analysis and the nature of this
proline to leucine substitution at codon 69 remains unclear. In human
cancers, the contribution of different human p53 polymorphic
variants to tumour development remains poorly defined. However,
evidence does exist for an association between the polymorphic
status at Pro72Arg and human cervical cancer (Storey et al, 1998).
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Figure 1 Identification of a mutant p53 allele within the solid mammary
carcinoma from patient 5. The exon 5 p53 cDNA sequence from normal and
tumour tissue is shown along with the non-coding strand sequence
substitution. Codon positions are shown to the right of the DNA sequence
Figure 2 Identification of a tumour-associated mutant p53 allele within
patient 6. The exon 2 p53 cDNA sequence from mammary tumour tissue is
depicted along with the non-coding strand sequence substitutions. Codon
positions are shown to the left of the DNA sequence
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ACGTConformation of mutant p53 proteins
A large number of tumour-associated p53 mutations found in
human cancer affect the conformation of the p53 protein resulting
in reactivity with antibody 240 (Gannon et al, 1990). These
PAb240-positive mutations are clustered within the flexible central
core domain of the p53 protein. In order to determine if the location
of point mutations within canine p53 affects protein conformation,
we performed in vitro translation and immunoprecipitation
analyses using the p53 mutants isolated from patients 5 and 6. The
Ala125Val mutation of patient 5 is located within the core domain
of p53, whereas the multiple p53 mutations identified in patient
6 reside within the N-terminal region. Each mutant p53 cDNA
produced full length protein when expressed in vitro (Figure 5).
Significant reactivity with antibody 240 was observed for the core
mutant (Ala125Val) when compared with wild-type canine p53
protein (Figure 5). In contrast, no change in antibody 240 reactivity
was seen for the N-terminal mutant p53 protein (Figure 5). These
results demonstrate, for the first time, that the position of codon
substitution in canine p53 affects protein conformation in a manner
similar to that observed for human p53.
DISCUSSION
Mutations within the p53 gene are observed in approximately 25%
of human breast cancer patients and may be associated with poor
prognosis and shorter overall survival rates (Casey et al, 1996;
Béroud and Soussi, 1998). Recently, similar p53 mutations have
been identified in primary mammary tumours of canine patients.
These include point mutations at codons 236, 245 and 249 (human
codon positions) within exon seven of the p53 gene (van Leeuwen
et al, 1996; Mayr et al, 1998). Non-sense, frame-shift, and splice-
site p53 mutations have also been described in canine mammary
cancer (Chu et al, 1998). In the present study, we have identified
three out of ten patients that exhibit alterations within the p53 gene
isolated from primary mammary tumour tissue. These p53 muta-
tions were located within exons two, four and five (see Figure 6).
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Figure 3 Characterization of a germline deletion within one p53 allele of
patient 9. (A) DNA sequence of the p53 allele from patient 9 containing a
deletion of exons three to seven. Exon sequences are shaded. The dashed
vertical line shows the proposed location of the DNA deletion event.
(B) Direct detection of the p53 deletion mutation within genomic DNA
isolated from normal (lanes 5 and 6) and tumour (lanes 8 and 9) tissue.
Amplification of exons 5–7 from the second intact p53 allele isolated from
normal and tumour tissue is also shown (lanes 4 and 7). Genomic DNA
isolated from a healthy dog was included as a wild-type control (lanes 1–3)
Figure 4 Location of a single base pair substitution within the intact p53
allele of patient 9. DNA sequence from exon 4 of the p53 gene isolated from
normal and tumour tissue is shown. The C to T transition at codon 69 is
depicted. Codon positions are shown to the left of the non-coding strand
DNA sequence
Figure 5 Conformation of mutant canine p53 protein. Radiolabelled wild-
type and mutant p53 proteins were expressed in vitro and
immunoprecipitated using antibodies 240 and 421. Antibody 416 was
included as a negative control. Antibody-bound p53 protein was resolved on
a 15% SDS-PAGE. Mutant p53 derived from patient 5 is labelled ‘core’, while
patient 6 mutant p53 is identified by ‘NT’. Minor differences in the migration
of the NT mutant protein compared with wild-type p53 may be due to the
location of amino acid substitutions within the transactivation domain of p53Although the number of canine patients analysed was small, the
frequency of p53 mutation (30%) appears similar to that observed
in human breast cancer patients.
Patient 5 presented with two discrete mammary tumours that
included an adenoma and a solid carcinoma which displayed a
high metastatic potential. The Ala125Val mutant p53 gene was
isolated from the carcinoma indicating that the more aggressive
mammary tumour of patient 5 was associated with a point muta-
tion of the canine p53 gene. Such an association between p53
mutation and high grade tumours has been noted previously in
human breast cancer patients (Faille et al, 1994; Berns et al, 1996;
Hartmann et al, 1997). The observed C to T transition mutation of
patient 5 may have been the result of de-amination of 5-methyl-
cytosine at the CpG position within codon 125 (GCG). In the
human p53 gene, CpG dinucleotides within exons 5–8 are
completely methylated in a tissue-independent manner and are,
therefore, vulnerable to this form of DNA damage (Tornaletti and
Pfeifer, 1995). A similar situation is likely to exist for the canine
p53 gene.
The Ala125Val p53 protein translated in vitro displayed an
increased mutant conformation as determined by antibody 240
reactivity. This is consistent with a number of human p53 mutants
that contain amino acid substitutions within the highly conserved
central core domain (for example, see Rolley et al, 1995).
Adoption of the mutant conformation is suggested to contribute to
nuclear accumulation of mutant p53 protein within tumour cells
(Faille et al, 1994). Indeed, the corresponding human p53 mutant,
Ala138Val, has been shown to display an increase in nuclear p53
protein levels within breast cancer cells (Moll et al, 1992; Faille
et al, 1994). Thus, it is likely that Ala125Val p53 would show an
increase in protein stability within the mammary carcinoma of
patient 5.
In some instances, the human p53 gene can be the target of
multiple mutations that arise from ‘stuttering’ of the DNA poly-
merase during replication (for examples see Strauss, 1997). In
20% of these cases, at least one of the base pair substitutions is
silent (Strauss, 1997). In the present study, the p53 allele from
patient 6 contained a cluster of three point mutations at codons 21,
22 and 24 that included a silent codon substitution at Leu22
(TTG to CTG) (see Figure 6). The identification of this mutant
p53 sequence indicates that a similar ‘hypermutation’ mechanism
exists in dogs and may target the canine p53 gene.
Two human breast cancer patients have been identified with
multiple p53 mutations clustered within the central core domain of
p53 (Glebov et al, 1994; Seth et al, 1994). In contrast, the muta-
tions within canine p53 derived from patient 6 are clustered within
the N-terminal domain of the protein. This region of p53
(including residues Phe19, Leu22, Trp23, and Leu26) is crucial for
both transactivation activity and MDM2 binding and is highly
conserved between human and canine p53 proteins (Lin et al,
1995; Kussie et al, 1996: Veldhoen and Milner, 1998). It is inter-
esting to note that the cluster of p53 mutations identified in the
tumour of patient 6 (see Figure 6) overlaps this critical region for
p53 protein function. Two of these mutations (Glu21Asp and
Leu22Leu) are conservative in nature and it remains unclear as to
whether they would significantly alter p53 protein activity in vivo.
Inherited p53 gene mutations have been linked to the
Li–Fraumeni syndrome and familial cancer predisposition (for a
review see Malkin, 1994; Birch et al, 1998). Studies performed in
mouse models also indicate that loss or inactivation of only one p53
allele is sufficient to promote cancer formation (Venkatachalam et
al, 1998). Due to the apparent breed predisposition to cancer
observed in dogs (see Priester and McKay, 1980), we have deter-
mined the status of the p53 gene in both normal and tumour cells
from canine patients. The identification of p53 mutations in normal
tissue strongly supports a germ line origin for these alterations in
the p53 gene. At present, two patients have been identified as
germline carriers for p53 mutations. These include a Bull Mastiff
with lymphoma containing a frame-shift p53 mutation (Veldhoen et
al, 1998) and a Boxer with mammary cancer containing an internal
deletion within the p53 gene (patient 9, this study). Both of these
breed types are found to display a high cancer frequency in the
canine population and the characterization of these patients
supports a link between heritable p53 gene mutations and breed
predisposition to cancer. A more extensive analysis of the p53 gene
status in breeds at greater risk for cancer will help to determine the
relationship between germ line p53 mutations and cancer predispo-
sition in the dog. Such information will be invaluable for breeding
out cancer predisposition in identified lineages.
In addition to germline deletion in one p53 allele, patient 9 also
displayed a germline base pair substitution at codon 69 in the second
p53 allele (codon 82 in human p53). This substitution results in a
codon change of proline to leucine and was also observed in the
p53 sequence isolated from the tumour tissue of patient 6. Whether
this sequence modification represents a polymorphism within the
proline-rich region of canine p53 or simply a point mutation share
by patients 6 and 9 remains unclear. However, preliminary analysis
in our laboratory of the p53 status in an independent group of canine
cancer patients lends support for the assignment of Pro69Leu as a
p53 sequence polymorphism (data not shown).
A number of sequence polymorphisms occur in the human p53
gene including base pair substitutions at codons 21, 36, 47, 72,
148 and 213 (Béroud and Soussi, 1998). The most common p53
sequence polymorphism in humans is Arg/Pro at codon 72 (Ara
et al, 1990). Recent reports indicate that individuals homozygous
for Arg 72 may be predisposed to non-small-cell lung carcinoma
(Tagawa et al, 1998) and/or human papillomavirus-associated
cervical cancer (Storey et al, 1998). A similar situation could exist
within canine cancer where the polymorphic status of the p53 gene
(for example Pro69Arg of patient 9) represents a cancer risk factor.
However, independent human studies have argued against a signif-
icant association between the p53 polymorphic status at position
72 and predisposition to cervical cancer (Helland et al, 1998;
Minaguchi et al, 1998; Rosenthal et al, 1998) and the role, if any,
that p53 polymorphisms play in tumorigenesis is uncertain.
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Patient 9
CCC      CTC
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GCG        GTG
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GAA GAT
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N24  K24
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Figure 6 Summary of DNA sequence changes identified in the p53 gene of
three canine mammary cancer patients. The position of each point mutation
is depicted by dashed lines. The location of DNA break points within one p53
allele of patient 9 is shown by an asteriskIn summary, three of the ten canine cancer patients were found
to contain mutations in the p53 gene (Figure 6). Tumour-
associated p53 mutations were identified in patients 5 and 6, while
germ line modifications were observed in both p53 alleles derived
from patient 9. These results contribute to our understanding of the
role of p53 inactivation in canine neoplasia and highlight the
strong parallels between the molecular basis of cancer in dogs and
humans. Moreover, our observations help to identify p53 inactiva-
tion as a possible factor in breed predisposition to cancer.
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